EHA 2019 Introduction of a new fixedduration targeted therapy with venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukaemia and coexisting comorbidities

EHA 2019: Introduction of a new fixed-duration targeted therapy with venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukaemia and coexisting comorbidities

The current standard of care for patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions is fixed duration chemoimmunotherapy or continuous and indefinite targeted therapy. As an answer to an unmet clinical need we developed a new...

More From BioPortfolio on "EHA 2019: Introduction of a new fixed-duration targeted therapy with venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukaemia and coexisting comorbidities"